Merck's Phase III Pipeline
| Drug | Indication | Status |
| MK-7418 (rolofylline) | Acute heart failure | NDA anticipated in 2009 |
| MK-0974, telcagepant | Migraine | NDA anticipated in 2009 |
| MK-8669 (deforolimus) | Cancer | NDA anticipated in 2010. |
| V503 | HPV Vaccine | Phase III clinical program is underway; NDA anticipated in 2012. |
| V503 MK-0822, odanacatib | Osteoporosis | The Phase III program is ongoing; NDA anticipated in 2012 |
| MK-0822, odanacatib MK-0524A (Cordaptive) | Hypercholesterolemia or mixed dyslipidemia | The cardiovascular outcomes trial is expected to be completed in 2012; NDA anticipated in 2012. |
| MK-0524A (Cordaptive) | Hypercholesterolemia or mixed dyslipidemia Hypercholesterolemia | The cardiovascular outcomes trial is expected to be completed in 2012; NDA anticipated in 2012. |
| MK-0859 (anacetrapib) | Hypercholesterolemia or mixed dyslipidemia Hypercholesterolemia | Phase III trials underway. NDA anticipated in beyond 2014. |
| V710 | Staphylococcus aureus (S. aureus) vaccine | NDA anticipated in 2011. |
| MK-0633 | Asthma and COPD | NDA anticipated in 2011. |
Related Articles:
Merck to create biotech unit
Merck kills controversial obesity med
Merck - Top 13 Advertising Budgets
Merck, Schering-Plough stocks take a dive
